Table 3.

Percentages of women receiving AOM by fracture risk factors

	GLOW USA cohort (n=27,957)		Low risk (n=3013)		High risk (n=3699)
	%	p-valuea	%	p-valuea	%	p-valuea
	Total	22.4		13.4		35.7
Education		0.94		0.96		0.007
High school or less	22.4		13.4		32.8
More than high school	22.5		13.5		37.3
Race		<0.0001		0.97		<0.0001
White	23.5		13.5		36.6
Non-white	16.2		13.4		24.8
Number of comorbidities		0.57		0.01		0.26
0	22.9		15.7		38.2
≥1	22.5		12.1		35.4
General health		0.01		0.2		0.03
Excellent/very good/good	22.7		13.6		36.7
Fair/poor	21.0		10.5		32.1
Prescription drug coverage		<0.0001		<0.0001		0.004
No	13.4		2.5		27.5
Yes	23.2		14.0		36.5
Concern about osteoporosis		<0.0001		<0.0001		<0.0001
Very/somewhat	25.2		15.2		39.0
Not at all	6.3		2.0		11.9
Perceived fracture risk		<0.0001		<0.0001		<0.0001
Same/lower than others	17.3		9.6		27.5
Higher than others	43.5		40.5		53.6
Vitality score		<0.0001		<0.001		0.001
≤median (62.5)	21.2		10.9		33.5
>median (62.5)	24.0		15.6		39.0
Physical function score		0.12		0.001		0.03
≤median (85)	22.0		10.0		34.4
>median (85)	22.8		14.7		37.9

AOM, anti-osteoporosis medication; GLOW, Global Longitudinal study of Osteoporosis in Women.

^ap values are from chi-square tests of differences in percentage treated between rows within risk groups.